Home / Stocks / Albert David Limited
ALBERTDAVD

Albert David Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹755.35

Change

-4.55 (-0.6%)

Open

₹755.1

Prev. Close

₹759.9

Day High

₹767.35

Day Low

₹754.1

Volume Analysis

Traded

818

Delivered

690

Delivery %

84.35%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Below-average fundamentals quality score (43/100)
  • •Low operating margin (1.7%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹777.01 ₹772.18 ₹763.76 ₹758.93 ₹750.51 ₹745.68 ₹737.26
Fibonacci ₹772.18 ₹767.12 ₹763.99 ₹758.93 ₹753.87 ₹750.74 ₹745.68
Camarilla ₹758.99 ₹757.78 ₹756.56 ₹758.93 ₹754.14 ₹752.92 ₹751.71

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+2.14%

1 Week

-4.26%

1 Month

-1.76%

3 Months

-12.59%

6 Months

+7.02%

1 Year

-5.73%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-0.24%

Net margin -0.3% × asset turnover 0.6x × equity multiplier 1.31x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Albert David Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Below-average fundamentals quality score (43/100); low operating margin (1.7%).

TopFund Score — Fundamentals Quality

43/100 — Weak

Data confidence: 70/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

15

Cash Flow

0

Corporate Governance

56

Institutional Ownership

31

Business Quality

35

Risk & Volatility

61

Liquidity

50

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication-Regarding Extract of Unaudited Financial Results for the quarter and half year ended 30th September, 2026

Board approved unaudited Q2 and half-year FY2026 results on November 12, 2026.

Submitted Regulation 74(5) compliance certificate for July 1-September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 93 88 89 89 98 83 75 71 87 90 86 101 101
Expenses + 77 80 79 88 92 82 80 81 85 79 83 91 89
Operating Profit 16 8 10 1 6 1 -5 -11 3 11 3 11 12
OPM % 17.14% 9.47% 10.75% 0.98% 6.32% 0.82% -6.34% -15.11% 2.91% 12.04% 3.21% 10.5% 11.55%
Other Income + 12 17 10 23 21 -9 -5 22 -2 12 -25 28 -4
Interest 0 0 0 0 0 0 0 1 1 1 0 1 0
Depreciation 1 2 2 2 2 2 2 2 2 2 3 2 3
Profit before tax 27 23 18 22 25 -10 -12 8 -3 20 -25 36 5
Tax % 23.54% 20.14% 28.77% 14.6% 28.09% -7.68% -12.53% 5.92% 27.91% 23.1% -15.06% 10.62% 43.42%
Net Profit + 20 19 13 19 18 -9 -10 8 -3 15 -21 32 3
EPS in Rs 36 33 23 33 32 -16 -18 14 -6 27 -38 56 5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 1 18 9 -3 6 -6 -16 -21 -11 8 15 44 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 317 318 293 285 316 320 246 313 341 362 345 333
Expenses + 281 286 266 267 286 289 227 272 297 315 342 327
Operating Profit 37 31 27 18 30 30 19 41 44 47 3 6
OPM % 12.0% 10.0% 9.0% 6.0% 10.0% 10.0% 8.0% 13.0% 13.0% 13.0% 0.9% 1.7%
Other Income + 2 43 8 9 15 7 17 16 15 58 30 7
Interest 3 2 1 1 1 1 1 1 1 0 1 3
Depreciation 15 9 8 8 7 8 8 9 9 7 7 10
Profit before tax 20 63 26 18 38 29 27 47 51 97 25 1
Tax % 32.0% 24.0% 39.0% 45.0% 29.0% 34.0% 19.0% 25.0% 29.0% 22.0% 32.0% 379.0%
Net Profit + 14 48 16 10 27 19 22 35 36 75 17 -1
EPS in Rs 24 84 28 17 47 34 39 62 63 132 30 -3
Dividend Payout % 23.0% 7.0% 20.0% 32.0% 13.0% 21.0% 15.0% 15.0% 14.0% 9.0% 17.0% -192.0%
Sales growth 11 0 -8 -3 11 1 -23 27 9 6 -5 -4

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 87 131 177 180 205 217 239 274 306 377 387 386 416
Borrowings + 30 20 30 28 0 2 2 6 5 3 12 30 34
Other Liabilities + 71 67 71 76 84 95 95 116 106 112 107 98 98
Total Liabilities 193 224 285 290 295 320 341 401 423 498 511 519 554
Fixed Assets + 49 44 87 83 77 91 84 88 80 83 99 100 119
CWIP 5 5 9 5 5 2 1 1 3 7 2 21 3
Investments 16 48 59 68 113 122 138 183 193 273 260 243 269
Other Assets + 122 127 130 134 99 106 119 130 148 135 151 155 162
Total Assets 193 224 285 290 295 320 341 401 423 498 511 519 554
Equity Capital 6 6 6 6 6 6 6 6 6 6 6 6 6

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 28 68 20 30 32 30 37 40 11 46 -28 -8
Cash from Investing Activity + -9 -38 -36 -11 -19 -20 -37 -40 -5 -33 23 -4
Cash from Financing Activity + -18 -18 7 -5 -17 -10 -2 -2 -6 -8 0 12
Net Cash Flow 1 12 -10 15 -4 0 -2 -1 -1 4 -5 0
Free Cash Flow 18 62 0 31 45 15 35 32 6 35 -43 -36
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 95 303 115 204 126 149 202 129 59 131 -629 -47

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 62.04% → 62.23%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 35.6% 35.23% 35.41% 35.36% 35.39% 35.12% 35.27% 35.5% 35.51% 35.52% 35.56% 35.53%
Promoters 62.04% 62.13% 62.13% 62.13% 62.13% 62.23% 62.23% 62.23% 62.23% 62.23% 62.23% 62.23%
FII 0.7% 0.98% 0.8% 0.88% 0.86% 1.0% 0.84% 0.6% 0.6% 0.58% 0.57% 0.6%
DII 1.67% 1.67% 1.67% 1.63% 1.63% 1.64% 1.65% 1.65% 1.65% 1.65% 1.63% 1.63%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Albert David Limited (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Albert David Limited?

Frequently Asked Questions about Albert David Limited

Community Sentiment

What are other investors saying about Albert David Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.